Related Experiment Video
Updated: Jun 6, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection
Nicole Le Saux1, Julie A Bettinger, Susan Wootton
1Children's Hospital of Eastern Ontario Research Institute and the University of Ottawa, Ottawa, Ontario;
Abstract:
Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccine-preventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the 'value added' by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Cryptococcal Meningitis
Determinants of Bacterial Pathogenicity and Virulence
Streptococcal Pharyngitis

